NewsPublic figure
Jimmy Carter's Melanoma: What His Story Taught the World About Immunotherapy
In 2015, President Jimmy Carter shared that he had metastatic melanoma. His openness helped millions learn about a newer kind of cancer treatment.
A plain-language summary based on public reporting and trusted sources, linked below.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
What he announced, and when
The American Association for Cancer Research summarized the sequence. In August 2015, after surgery for a mass on his liver, tests revealed melanoma. Further tests found that it had spread to his brain. Jimmy Carter said he would have radiation to the brain and treatment with an immunotherapy drug.
Four months later he told his Sunday school class in Plains, Georgia, that he was cancer-free. CNN quoted his statement: "My most recent MRI brain scan did not reveal any signs of the original cancer spots nor any new ones. I will continue to receive regular three-week immunotherapy treatments of pembrolizumab."
Carter died in December 2024 at the age of 100.
His case became a public introduction to a change that was already underway in oncology. It is worth explaining properly, along with the disease itself.
Melanoma is a pigment-cell cancer
Melanoma starts in melanocytes, the cells that make the pigment melanin. The National Cancer Institute (NCI) notes these cells come from the neural crest during development. Most melanomas arise in skin, but they can also start on mucosal surfaces and inside the eye.
Its reputation for spreading is earned. Melanoma can reach the liver, the lungs, the bones, and the brain, which is why a skin cancer can present as a mass in an organ.
Where it appears, and a common misconception
Many people believe melanoma always develops from an existing mole. NCI states otherwise: more than 50% of cases arise in apparently normal areas of skin.
Location varies by sex. NCI reports melanoma occurs more commonly on the arms and legs in women, and on the trunk or head and neck in men. The back is a classic blind spot.
ABCDE, plus the signs that come first
NCI lists early changes in a mole that suggest something is wrong: darker or uneven discoloration, itching, growth or the appearance of satellite spots nearby, and, as later signs, ulceration or bleeding.
The familiar checklist is ABCDE:
- Asymmetry of the lesion
- Border irregularity
- Color variation
- Diameter greater than 6 mm
- Evolution, meaning any change over time
Six millimeters is roughly the width of a pencil eraser. Evolution is the most useful letter of the five, because change over weeks or months matters more than any single feature.
Get it looked at
Book an appointment for any of these:
- A mole that has changed in size, shape, color, or texture over the past few months
- A new dark spot appearing in adulthood that does not resemble your other moles
- A spot that itches persistently, bleeds, crusts, or fails to heal within four weeks
- A dark streak under a fingernail or toenail with no injury to explain it
- A new dark spot on a palm, a sole, or inside the mouth
Check your whole skin, not just sun-exposed parts. That means the scalp, the soles, and between the toes. Ask someone to look at your back, since you cannot.
Melanoma is far more common in people with lighter skin. SEER, the federal cancer surveillance program, puts the melanoma death rate at 3.8 per 100,000 for non-Hispanic White men against 0.4 for non-Hispanic Black men. But it occurs in every skin tone, and spots on palms, soles, and nails deserve the same attention in everyone.
One rule about the biopsy
NCI is specific here, and the instruction is worth knowing before you are in the room.
A biopsy, "preferably by local excision," should be done for any suspicious lesion. And then this: "Suspicious lesions should never be shaved off or cauterized."
The reason is that the single most important measurement is how deep the melanoma has grown. Shaving or burning a lesion destroys the tissue needed to make that measurement.
What the pathologist is measuring
Two features carry most of the prognostic weight. Breslow thickness is the depth of the tumor in millimeters. Ulceration is whether the skin surface over the tumor has broken down.
NCI reports something reassuring about these two in particular. In a study where expert dermatopathologists reviewed the same slides, agreement was highest for Breslow thickness and ulceration, and poor for other features such as Clark level, regression, and lymphocytic infiltration. The two measurements that matter most are also the most reliable.
Staging then uses the AJCC system, combining tumor features, lymph node involvement, and distant spread. Sentinel lymph node biopsy, sampling the first node the area drains into, identifies nodes that look normal but contain cancer.
Why 2015 was a turning point
Pembrolizumab belongs to a class called immune checkpoint inhibitors. Cancer cells can display proteins that act as brakes on T cells, the immune system's attack cells. These drugs release the brake.
Ipilimumab was the first checkpoint inhibitor approved by the FDA in this setting. NCI notes it improved overall survival at the higher of two amounts tested, compared with placebo, but that this came with significant toxicity. A later trial found the lower amount actually produced better overall survival.
Newer agents followed. In the CheckMate 238 trial, nivolumab produced better relapse-free survival than high-dose ipilimumab with a more tolerable safety profile. In KEYNOTE-054, pembrolizumab produced better relapse-free survival than placebo.
An honest caveat belongs here. These drugs transformed outcomes for many patients, and they do not work for everyone. They also carry real risks, because releasing an immune brake can cause the immune system to attack healthy organs.
The other route: targeting the mutation
The Cancer Genome Atlas analyzed 333 cutaneous melanomas and sorted them into four genomic subtypes: BRAF-altered, RAS-altered, NF1-altered, and triple wild-type.
For BRAF-altered melanoma, combining a BRAF inhibitor with a MEK inhibitor is FDA-approved and improves outcomes. That is why tumor genotyping is standard in advanced melanoma.
The numbers
SEER publishes an American Cancer Society projection of about 112,000 new melanomas and 8,510 deaths in the US in 2026. NCI's own measurement of five-year relative survival across all stages, taken from people diagnosed between 2016 and 2022, is 94.7%. Median age at diagnosis is 67.
By stage the picture separates sharply. Survival is 100.0% for localized disease, 76.0% for regional disease, and 34.0% for distant disease. Localized cases make up 77% of diagnoses, regional 10%, and distant only 5%.
That distant-stage figure was far lower before checkpoint inhibitors. These are population statistics collected over years, and they describe groups, not individuals.
Sources
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Melanoma (skin cancer). The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.